World’s leading cardiology groups say it is time to rethink RCTs

Michael Walter | December 16, 2022 | Cardiovascular Business | Policy & Regulations

Randomized clinical trials (RCTs) are an essential step in the development of new therapies. According to a new joint statement from four of the world’s leading cardiology groups, however, the rules and regulations that govern these trials have grown too complex—and the costs require to carry them out are far too high.

The American College of Cardiology (ACC), American Heart Association (AHA), European Society of Cardiology (ESC) and World Heart Federation (WHF) all collaborated on the statement. It can be read in full in the Journal of the American College of Cardiology, Circulation, European Heart Journal and Global Heart.[1-4]

“Randomized trials are the gold-standard method for evaluating new therapies and improving patient care,” ESC President Franz Weidinger, MD, said in a prepared statement. “However, the cost and complexity of trials are becoming prohibitive. Cardiology provided the foundation for an era of highly successful clinical trials and is well placed to lead the way on modernization.”

The document includes a variety of recommendations for updates that would make RCTs easier—and more cost-effective—for research teams to carry out. For example, the groups noted that hospitals were able to participate in RCTs during the COVID-19 pandemic by focusing only on essential data, leaving the collection of follow-up data to electronic health records and other helpful resources. Remote monitoring and smartphone-based data collection were also found to be helpful during the pandemic—and these are tools that could be used in many RCTs going forward, the groups wrote.

“The pandemic reinforced the value of digital technology in healthcare and demonstrated the power of partnerships in global health,” WHF President Fausto Pinto, MD, PhD, said in the same statement. “It also showed the importance of using digital tools to improve the organization, development, and implementation of clinical trials, essential to drive innovation in care and meet unexpected challenges such as a pandemic.”

“In a rapidly changing and increasingly global world, there is no excuse for clinical trials not to keep pace with recent advances,” added ACC President Edward T.A. Fry, MD.

Cardiologists fear new regulations will cause a medical device shortage in Europe

Most devices implanted during LAAO procedures are oversized—and patients benefit

FDA changes indications for Impella RP heart pump after dramatic shift in mortality rate

Cardiologist urges physicians to promote plant-based diets: ‘We owe it to the profession, our patients and the planet’

Telehealth for cardiovascular disease patients: 3 key benefits and 5 ongoing challenges

Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Health Exec

Major association of physicians presents itself as a go-to alternative vs. the government on vaccine expertise

One of the most formidable societies of medical professionals in the U.S. is going toe-to-toe with Robert F. Kennedy’s HHS over changing vaccination recommendations.

Health Exec

Tom Price: Medical residency slots need to expand to combat physician shortages

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

Health Imaging

Tariffs will have a significant impact on the nuclear imaging supply chain in the US

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.